Intravenous Bisphosphonate–Associated Osteonecrosis of the Jaw

• Autores: Lewis A. Humbert, Georgia K. Johnson, Thomas A. Statz, Janet M. Guthmiller
• Localización: Journal of periodontology, ISSN 0022-3492, Vol. 78, Nº. 11, 2007, págs. 2203-2208
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Intravenous Bisphosphonate–Associated Osteonecrosis of the Jaw Thomas A. Statz,* Janet M. Guthmiller,* Lewis A. Humbert,* and Georgia K. Johnson* *Department of Periodontics, College of Dentistry, The University of Iowa, Iowa City, IA.

    Correspondence: Dr. Georgia K. Johnson, Department of Periodontics, College of Dentistry, The University of Iowa, Iowa City, IA 52242. Fax: 319/335-7239; e-mail: georgia-johnson@uiowa.edu.

    Background: Bisphosphonates have received attention in the dental and medical scientific literature because of spontaneous necrosis of the jaw subsequent to their use. As the population ages, the use of these medications is increasing; the medical benefits seem to outweigh the risk for osteonecrosis of the jaw (ONJ).

    Methods: A 71-year-old white male with a history of multiple myeloma, for which he was receiving intravenous (IV) zoledronic acid, presented for routine periodontal maintenance therapy. Intraoral observation revealed a 9 × 4-mm area of exposed bone on the lingual aspect of tooth #31. Initially, the site was treated conservatively with topical 0.12% chlorhexidine gluconate application. Over a 12-month period, the area of exposed bone increased in size to 20 × 9 mm and became symptomatic.

    Results: The osseous necrosis progressed, ultimately resulting in a pathologic fracture of the right posterior mandible that was managed by reduction and stabilization. At 5 months post-surgery, bone exposure persisted in the region, and a new site of osteonecrosis developed on the contralateral side of the jaw.

    Conclusions: ONJ associated with IV bisphosphonate therapy is extremely difficult to manage. Dental treatment of ONJ should be conservative and provide relief to the patient. Patients with cancer who are candidates for IV bisphosphonate therapy should be informed of the potential risks and be referred for dental evaluation. Dentists should collaborate with physicians to minimize the risk for ONJ.

    KEYWORDS: Bisphosphonates, multiple myeloma, osteonecrosis Cited by S.N. Rogers, N.O.A. Palmer, D. Lowe and C. Randall. (2015) United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis. British Journal of Oral and Maxillofacial Surgery 53, 176-182.

    Online publication date: 1-Feb-2015.

    CrossRef L. Lo Russo, D. Ciavarella, C. Buccelli, O. Di Fede, G. Campisi, L. Lo Muzio, G. Pellegrino and P. Di Lorenzo. (2014) Legal liability in bisphosphonate-related osteonecrosis of the jaw. BDJ 217, 273-278.

    Online publication date: 26-Sep-2014.

    CrossRef F. Carini, K. Pavanello, V. Pisapia, G. Gatti and G. Porcaro. (2012) Osteonecrosi spontanea dei mascellari in relazione all’assunzione di bisfosfonati endovenosi: caso clinico. Italian Oral Surgery 11, 296-302.

    Online publication date: 1-Dec-2012.

    CrossRef Ami Smidt, Mordekhai Lipovetsky-Adler and Eldad Sharon. (2012) Forced eruption as an alternative to tooth extraction in long-term use of oral bisphosphonates. The Journal of the American Dental Association 143, 1303-1312.

    Online publication date: 1-Dec-2012.

    CrossRef Paolo Vescovi, Maddalena Manfredi, Elisabetta Merigo, Rebecca Guidotti, Marco Meleti, Giuseppe Pedrazzi, Carlo Fornaini, Mauro Bonanini, Teore Ferri and Samir Nammour. (2011) Early Surgical Laser-Assisted Management of Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ): A Retrospective Analysis of 101 Treated Sites with Long-Term Follow-Up. Photomedicine and Laser Surgery, 111104095447008.

    Online publication date: 4-Nov-2011.

    CrossRef Hamad A. Alzoman. (2011) Prevalence of jaw osteonecrosis among patients receiving bisphosphonates in Riyadh. King Saud University Journal of Dental Sciences 2, 29-32.

    Online publication date: 1-Jul-2011.

    CrossRef S.S. Huja, S.A. Fernandez, Christina Phillips and Y. Li. (2009) Zoledronic acid decreases bone formation without causing osteocyte death in mice. Archives of Oral Biology 54, 851-856.

    Online publication date: 1-Sep-2009.

    CrossRef Sunil J Wimalawansa. (2008) Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opinion on Drug Safety 7:10.1517/eds.2008.7.issue-4, 491-512.

    Online publication date: 1-Jul-2008.

    CrossRef (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:10.1002/pds.v17:6, i-xvi.

    Online publication date: 1-Jun-2008.